Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,465.59 -3.71 (-0.07%) Dow
38,972.12 -140.04 (-0.36%) Nasdaq
17,762.75 +45.09 (+0.25%) Bitcoin USD
61,752.57 +562.60 (+0.92%) CMC Crypto 200
1,279.73 -4.05 (-0.32%)
ITCI Jan 2025 90.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:26PM EDT. Market open.
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 2.4000 |
| Ask | 4.1000 |
| Strike | 90.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.